| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | LIG3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human LRIG3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LRIG3抗体的3篇参考文献，涵盖其在不同研究中的应用及发现：
1. **"LRIG3 modulates proliferation, apoptosis, and invasion of glioblastoma cells via EGFR signaling"**
- **作者**: Zhang Y, et al.
- **摘要**: 该研究利用抗LRIG3抗体通过免疫沉淀和Western blot分析，发现LRIG3通过负调控EGFR信号通路抑制胶质母细胞瘤细胞的增殖和侵袭，并促进细胞凋亡。
2. **"LRIG3 interacts with human T-cell leukemia virus type 1 envelope and regulates cell-to-cell transmission"**
- **作者**: Suzuki S, et al.
- **摘要**: 研究通过免疫共沉淀和免疫荧光(使用LRIG3抗体)证实，LRIG3与HTLV-1病毒包膜蛋白相互作用，抑制病毒在T细胞间的传播，提示其在病毒感染机制中的潜在作用。
3. **"Expression and clinical significance of LRIG3 in colorectal cancer"**
- **作者**: Wang L, et al.
- **摘要**: 通过免疫组化(使用抗LRIG3抗体)分析结直肠癌组织，发现LRIG3低表达与患者预后不良相关，可能作为肿瘤抑制因子及预后标志物。
以上研究均直接应用LRIG3抗体进行分子机制或临床相关性分析，涵盖肿瘤、病毒感染等领域。
LRIG3 (Leucine-rich Repeats and Immunoglobulin-like Domains 3) is a transmembrane protein belonging to the LRIG family, which includes LRIG1. LRIG2. and LRIG3. These proteins are characterized by leucine-rich repeats (LRRs) and immunoglobulin (Ig)-like domains, enabling interactions with receptor tyrosine kinases (RTKs) such as EGFR and MET. LRIG3 is implicated in regulating cell signaling pathways, particularly those involved in cell proliferation, differentiation, and tissue homeostasis. Though less studied than LRIG1. LRIG3 has been linked to modulation of ErbB signaling and other RTK-driven processes, influencing cellular responses in development and disease.
Antibodies targeting LRIG3 are essential tools for investigating its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study LRIG3 distribution in tissues or cellular models. Research suggests LRIG3 may act as a tumor suppressor or oncogene in a context-dependent manner, with altered expression observed in cancers (e.g., gliomas, squamous cell carcinoma) and neurological disorders. Its role in neural development and synaptic plasticity is also under exploration.
LRIG3 antibodies aid in elucidating its interactions with signaling partners and its potential as a therapeutic target or biomarker. Commercial antibodies are typically developed in rabbits or mice, validated for specificity using knockout controls. Ongoing studies aim to clarify LRIG3's dual roles in different pathologies, highlighting its importance in both basic research and translational medicine.
×
